Top

Published in:

01-06-2020 | Dyslipidemia | Original Article

HDL cholesterol efflux capacity is related to disease activity in psoriatic arthritis patients

Authors: Iván Ferraz-Amaro, María Vanesa Hernández-Hernández, Estefanía Armas-González, Hiurma Sánchez-Pérez, José David Machado, Federico Díaz-González

Published in: Clinical Rheumatology | Issue 6/2020

Abstract

Objective

Cholesterol efflux capacity (CEC) is the ability of high-density lipoprotein (HDL) cholesterol to accept cholesterol from macrophages. CEC is linked to cardiovascular events in the general population, and it has been shown to be disrupted in inflammatory states. The aim of this study was to establish whether CEC is impaired in PsA patients and if this could be explained by disease-related features like disease activity.

Methods

Case-control study that encompassed 105 individuals: 52 PsA patients and 53 controls. CEC, using an in vitro assay, and lipoprotein serum concentrations were assessed in patients and controls. Disease activity in patients with PsA was measured using the Disease Activity Index for Psoriatic Arthritis (DAPSA). Multivariate analysis was performed to study the differences between CEC in patients and controls, and the relation of CEC with PsA activity-related data and lipid profile.

Results

Total cholesterol, apolipoprotein A1, and LDL cholesterol serum levels were downregulated in PsA patients. CEC did not differ between controls and patients (17 ± 10 vs. 18 ± 2%, p = 0.15) after adjusting for traditional cardiovascular risk factors or other variations in the lipid profile related to the disease. Traditional cardiovascular risk factors, both in patients and controls, were not related to CEC. After multivariate regression analysis, the DAPSA score was inversely and independently associated with CEC (beta coefficient − 0.75 [95%CI − 1.39–− 0.11] %, p = 0.023).

Conclusion

CEC is inversely associated with disease activity in PSA patients, reinforcing the role of disease activity as a key factor in the development of accelerated atherosclerosis in these patients.

Key Points

• Cholesterol efflux capacity is linked to cardiovascular events in the general population.

• In patients with psoriatic arthritis, cholesterol efflux capacity is inversely associated with disease activity (beta coefficient − 0.75[95% CI − 1.39–− 0.11] %, p = 0.023).

• This finding reinforces the role of disease activity as a key factor in increasing cardiovascular risk in psoriatic arthritis patients.

Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT (2009) Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 68:1131–1135CrossRef

Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes I, Nurmohamed MT (2013) Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 72:211–216CrossRef

Eder L, Wu Y, Chandran V, Cook R, Gladman DD (2016) Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. Ann Rheum Dis 75:1680–1686CrossRef

Haroon M, Rafiq Chaudhry AB, Fitzgerald O (2016) Higher prevalence of metabolic syndrome in patients with psoriatic arthritis: a comparison with a control group of noninflammatory rheumatologic conditions. J Rheumatol 43:463–464CrossRef

Tobin AM, Veale DJ, Fitzgerald O, Rogers S, Collins P, O’Shea D, Kirby B (2010) Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol 37:1386–1394CrossRef

Jones SM, Harris CP, Lloyd J, Stirling CA, Reckless JP, McHugh NJ (2000) Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann Rheum Dis 59:904–909CrossRef

Tam LS, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, Li TK, Yu T, Zhu YE, Wong KC, Kun EW, Li EK (2008) Cardiovascular risk profile of patients with psoriatic arthritis compared to controls--the role of inflammation. Rheumatology (Oxford) 47:718–723CrossRef

Lazarevic MB, Vitic J, Mladenovic V, Myones BL, Skosey JL, Swedler WI (1992) Dyslipoproteinemia in the course of active rheumatoid arthritis. Semin Arthritis Rheum 22:172–178CrossRef

Skoczynska AH, Turczyn B, Barancewicz-Losek M, Martynowicz H (2003) High-density lipoprotein cholesterol in patients with psoriatic arthritis. J Eur Acad Dermatol Venereol 17:362–363CrossRef

10.

Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34:585–592CrossRef

11.

Cuchel M, Rader DJ (2006) Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation 113:2548–2555CrossRef

12.

Tall AR (2008) Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med 263:256–273CrossRef

13.

Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364:127–135CrossRef

14.

Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, Shaul PW (2014) HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 371:2383–2393CrossRef

15.

Tejera-Segura B, Macia-Diaz M, Machado JD, de Vera-Gonzalez A, Garcia-Dopico JA, Olmos JM, Hernandez JL, Diaz-Gonzalez F, Gonzalez-Gay MA, Ferraz-Amaro I (2017) HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis. Arthritis Res Ther 19:113CrossRef

16.

Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, Group CS (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673CrossRef

17.

Schoels MM, Aletaha D, Alasti F, Smolen JS (2016) Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 75:811–818CrossRef

18.

Prevoo ML, van’t Hoff MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48CrossRef

19.

Pincus T, Swearingen C, Wolfe F (1999) Toward a multidimensional health assessment questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum 42:2220–2230CrossRef

20.

Quevedo-Abeledo JC, Rua-Figueroa I, Sanchez-Perez H, Tejera-Segura B, de Vera-Gonzalez A, Gonzalez-Delgado A, Llorca J, Gonzalez-Gay MA, Ferraz-Amaro I (2019) Disease damage influences cardiovascular risk reclassification based on carotid ultrasound in patients with systemic lupus erythematosus. J Rheumatol 46:483–491CrossRef

21.

Gonzalez-Gay MA, Gonzalez-Juanatey C (2014) Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox. Ann Rheum Dis 73:1281–1283CrossRef

22.

Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, Gabriel SE (2011) Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 70:482–487CrossRef

23.

Robertson J, Peters MJ, McInnes IB, Sattar N (2013) Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 9:513–523CrossRef

24.

Charles-Schoeman C, Lee YY, Grijalva V, Amjadi S, FitzGerald J, Ranganath VK, Taylor M, McMahon M, Paulus HE, Reddy ST (2012) Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis 71:1157–1162CrossRef

25.

Ronda N, Favari E, Borghi MO, Ingegnoli F, Gerosa M, Chighizola C, Zimetti F, Adorni MP, Bernini F, Meroni PL (2014) Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 73:609–615CrossRef

26.

Ferraz-Amaro I, Hernandez-Hernandez MV, Tejera-Segura B, Delgado-Frias E, Macia-Diaz M, Machado JD, Diaz-Gonzalez F (2019) Effect of IL-6 receptor blockade on proprotein convertase subtilisin/kexin type-9 and cholesterol efflux capacity in rheumatoid arthritis patients. Horm Metab Res 51:200–209CrossRef

27.

Bellan M, Bor S, Gibbin A, Gualerzi A, Favretto S, Guaschino G, Bonometti R, Rossini A, Sola D, Pedrazzoli R, Carnevale Schianca GP, Pirisi M, Sainaghi PP (2018) Inflammatory markers predict insulin sensitivity in active rheumatoid arthritis but not in psoriatic arthritis. Reumatismo 70:232–240CrossRef

28.

van Mens LJJ, van de Sande MGH, van Kuijk AWR, Baeten D, Coates LC (2018) Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort. Ann Rheum Dis 77:251–257CrossRef

29.

Salaffi F, Ciapetti A, Carotti M, Gasparini S, Gutierrez M (2014) Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world. Biomed Res Int 2014:528105CrossRef

30.

Shen J, Wong KT, Cheng IT, Shang Q, Li EK, Wong P, Kun EW, Law MY, Yip R, Yim I, Ying S, Li M, Li TK, Wong CK, Zhu TY, Lee JJ, Chang M, Lee AP, Tam LS (2017) Increased prevalence of coronary plaque in patients with psoriatic arthritis without prior diagnosis of coronary artery disease. Ann Rheum Dis 76:1237–1244CrossRef

31.

Szentpetery A, Healy GM, Brady D, Haroon M, Gallagher P, Redmond CE, Fleming H, Duignan J, Dodd JD, FitzGerald O (2018) Higher coronary plaque burden in psoriatic arthritis is independent of metabolic syndrome and associated with underlying disease severity. Arthritis Rheum 70:396–407CrossRef

32.

Holzer M, Wolf P, Curcic S, Birner-Gruenberger R, Weger W, Inzinger M, El-Gamal D, Wadsack C, Heinemann A, Marsche G (2012) Psoriasis alters HDL composition and cholesterol efflux capacity. J Lipid Res 53:1618–1624CrossRef

33.

Holzer M, Wolf P, Inzinger M, Trieb M, Curcic S, Pasterk L, Weger W, Heinemann A, Marsche G (2014) Anti-psoriatic therapy recovers high-density lipoprotein composition and function. J Invest Dermatol 134:635–642CrossRef

34.

Salahuddin T, Natarajan B, Playford MP, Joshi AA, Teague H, Masmoudi Y, Selwaness M, Chen MY, Bluemke DA, Mehta NN (2015) Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis. Eur Heart J 36:2662–2665CrossRef

35.

Bhatt A, Rohatgi A (2016) HDL cholesterol efflux capacity: cardiovascular risk factor and potential therapeutic target. Curr Atheroscler Rep 18:2CrossRef

36.

Ormseth MJ, Yancey PG, Solus JF, Bridges SL Jr, Curtis JR, Linton MF, Fazio S, Davies SS, Roberts LJ 2nd, Vickers KC, Kon V, Michael Stein C, Investigators T (2016) Effect of drug therapy on net cholesterol efflux capacity of high-density lipoprotein-enriched serum in rheumatoid arthritis. Arthritis Rheum 68:2099–2105CrossRef

37.

Liao KP, Playford MP, Frits M, Coblyn JS, Iannaccone C, Weinblatt ME, Shadick NS, Mehta NN (2015) The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc 4

38.

Ronda N, Greco D, Adorni MP, Zimetti F, Favari E, Hjeltnes G, Mikkelsen K, Borghi MO, Favalli EG, Gatti R, Hollan I, Meroni PL, Bernini F (2015) Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism. Arthritis Rheum 67:1155–1164CrossRef

39.

Faresjo T, Faresjo A (2010) To match or not to match in epidemiological studies--same outcome but less power. Int J Environ Res Public Health 7:325–332CrossRef

Title: HDL cholesterol efflux capacity is related to disease activity in psoriatic arthritis patients
Authors: Iván Ferraz-Amaro
María Vanesa Hernández-Hernández
Estefanía Armas-González
Hiurma Sánchez-Pérez
José David Machado
Federico Díaz-González
Publication date: 01-06-2020
Publisher: Springer London
Keywords: Dyslipidemia
Psoriatic Arthritis
Published in: Clinical Rheumatology / Issue 6/2020
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-04961-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

HDL cholesterol efflux capacity is related to disease activity in psoriatic arthritis patients

Abstract

Objective

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2020

International league of associations for rheumatology recommendations for the management of psoriatic arthritis in resource-poor settings

No evidence of abnormal metabolic or inflammatory activity in the brains of patients with rheumatoid arthritis: results from a preliminary study using whole-brain magnetic resonance spectroscopic imaging (MRSI)

Glucocorticoid use is an independent risk factor for developing sarcopenia in patients with rheumatoid arthritis: from the CHIKARA study

Noninvasive positive pressure ventilator deteriorates the outcome of pneumomediastinum in anti-MDA5 antibody-positive clinically amyopathic dermatomyositis

Primary antiphospholipid syndrome, Addison disease, and adrenal incidentaloma

Demographic, clinical, and scintigraphic comparison of patients affected by palmoplantar pustulosis and severe acne: a retrospective study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page